Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on June 10, 2022. The report details a corporate governance action taken by the Board of Directors on the same date. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Ocuphire Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a bylaws amendment and does not contain financial statements or performance metrics.
Material Changes
The material change reported is an amendment to the Company's Second Amended and Restated Bylaws, effective immediately. Specifically, Section 8 of ARTICLE III was amended to reduce the quorum requirement for all stockholder meetings from a majority of the voting power of outstanding shares to one-third of the voting power of outstanding shares.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document is limited to the description of the bylaws amendment and the listing of exhibits.
Investor Verification Checklist
- Verify the exact text of the Bylaws Amendment filed as Exhibit 3.1 to confirm the new quorum threshold.
- Confirm the impact of the reduced quorum requirement on future stockholder meeting outcomes and corporate governance stability.
- Review recent 10-K or 10-Q filings for Ocuphire Pharma, Inc. to obtain current financial metrics, as this 8-K does not include them.